New Study Highlights the Use of MR-proADM in Assessing Disease Severity and Treatment Response in Patients with Sepsis and Septic Shock

Analysis shows the additional value of MR-proADM in formulating early escalation and de-escalation treatment strategies

HENNIGSDORF, GERMANY – (March 26, 2018) – In collaboration with the SepNet Critical Care Trials Group, a new analysis of 1089 patients with sepsis and septic shock across 33 German Intensive Care Units was recently published in Critical Care. The biomarker, mid-regional proadrenomedullin (MR-proADM), was found to add significant clinical value in identifying the likelihood of further disease progression, the earlier escalation of therapy in patients at risk of treatment failure, and the subsequent de-escalation of treatment and early discharge of low risk patients.

“Earlier indicators of developing organ dysfunction and treatment efficacy are essential in guiding therapeutic interventions in sepsis and septic shock”, said lead investigator Gunnar Elke, MD, intensive care consultant at the University Medical Centre Schleswig-Holstein, Kiel, Germany. “ The independent nature of MR-proADM in relation to PCT within the first 24 hours of therapy is crucial in providing a prompt indication concerning treatment efficacy and potential treatment failure. Incorporating MR-proADM into an early sepsis management protocol may help guide earlier clinical interventions or modify existing antimicrobial therapy in order to prevent further organ dysfunction development or disease progression”.

Increased levels of Adrenomedullin (ADM) are generated in disease conditions in order to stabilize the microcirculation and protect against vascular permeability1. However, the reliable measurement of ADM is complicated by its short half-life and rapid degradation. The stable fragment of the peptide, MR-proADM, allows the accurate quantification of incremental changes over the course of therapy. Recent evidence highlights the use of MR-proADM as a highly sensitive biomarker to assess disease severity in patients with sepsis2,3, with concentrations rapidly induced in the initial stages of sepsis development following burns4 and neurological disorders5, as well as in response to invasive fungal infections in septic shock patients6.

For more information, please see the following site: www.thermoscientific.com/proadrenomedullin

This product is not FDA cleared. Availability of this product is related to the registration status in the countries.

About The Sepsis Foundation

The Sepsis Foundation was founded in 2012 as a foundation under civil law. Based in Jena, Germany, the foundation aims to promote education, science, research and innovation for the early diagnosis, treatment, prevention and reduction of sepsis cases. The Sepsis Foundation is also the legal umbrella organization for the SepNet Study Critical Care Trials Group, a network of more than 100 physicians and scientists in approximately 50 clinics and universities across Germany, who carry out basic research and clinical studies in sepsis. As a member of the Global Sepsis Alliance, a global umbrella organization for over 50 country organizations, the foundation is closely involved in international sepsis initiatives. For more information, please visit http://www.sepsis-stiftung.eu.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.

References:

1. Xie Z, Chen WS, Yin Y, et al. Adrenomedullin surges are linked to acute episodes of the systemic capillary leak syndrome (Clarkson disease). J Leukoc Biol. 2018.

2. Andaluz-Ojeda D, Nguyen HB, Meunier-Beillard N, et al. Superior accuracy of mid-regional proadrenomedullin for mortality prediction in sepsis with varying levels of illness severity. Ann Intensive Care. 2017;7(1):15.

3. Bernal-Morell E, Garcia-Villalba E, Vera MDC, et al. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis. J Infect. 2017.

4. Gille J, Ostermann H, Dragu A, Sablotzki A. MR-proADM: A New Biomarker for Early Diagnosis of Sepsis in Burned Patients. J Burn Care Res. 2017;38(5):290-298.

5. Bustamante A, Garcia-Berrocoso T, Penalba A, et al. Sepsis biomarkers reprofiling to predict stroke-associated infections. J Neuroimmunol. 2017;312:19-23.

6. Decker SO, Sigl A, Grumaz C, et al. Immune-Response Patterns and Next Generation Sequencing Diagnostics for the Detection of Mycoses in Patients with Septic Shock-Results of a Combined Clinical and Experimental Investigation. Int J Mol Sci. 2017;18(8).

 

Contact Information: Dr. Rita Baxmann
Phone: +49 3302 883 303
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

thermo scientific applied biosystems invitrogen fisher scientific unity lab service